Stock Events

Stock Events

Bio-Path 

$0.038000
71
-$0.00-5% Monday 18:34

Statistics

Day High
0.038
Day Low
0.038
52W High
0.15
52W Low
0.01
Volume
1
Avg. Volume
32,308
Mkt Cap
351,196
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.4
0.61
1.61
2.62
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-270,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BPTH. It's not an investment recommendation.
Tesla
11
TSLA
NVIDIA
10
NVDA
Alphabet
10
GOOGL
Microsoft
9
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Bio-Path's nucleic acid-based treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in antisense technology, which is a direct competitor to Bio-Path's DNA/RNA-based drug development.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.76B
Arrowhead Pharmaceuticals develops drugs based on RNA interference, competing in the same space as Bio-Path's RNA-based therapies.
Moderna
MRNA
Mkt Cap27.09B
Moderna is a leader in mRNA technology, which is a form of nucleic acid therapy competing with Bio-Path's own DNA/RNA-based treatments.
BioNTech
BNTX
Mkt Cap23.14B
BioNTech SE, known for its mRNA-based vaccines, competes in the broader nucleic acid therapy space alongside Bio-Path.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on RNA-targeted therapeutics, particularly in genetic medicine, competing with Bio-Path's genetic intervention strategies.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of genetic medicine that competes with Bio-Path's gene-based therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, directly competing with Bio-Path's focus on genetic diseases.

About

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Show more...
CEO
Dr. Douglas P. Morris
Employees
1
Country
United States
ISIN
US09057N4097

Listings

OTC Link
US
BPTH

0 Comments

Share your thoughts

FAQ

What is Bio-Path stock price today?▼
The current price of BPTH is $0.04 USD — it has decreased by -5% in the past 24 hours. Watch Bio-Path stock price performance more closely on the chart.
What is Bio-Path stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Bio-Path stocks are traded under the ticker BPTH.
Is Bio-Path stock price growing?▼
BPTH stock has risen by +0% compared to the previous week, the month change is a +11.24% rise, over the last year Bio-Path has showed a -74.84% decrease.
What is Bio-Path market cap?▼
Today Bio-Path has the market capitalization of 351,196
When is the next Bio-Path earnings date?▼
Bio-Path is going to release the next earnings report on August 18, 2026.
What is Bio-Path revenue for the last year?▼
Bio-Path revenue for the last year amounts to 0 USD.
What is Bio-Path net income for the last year?▼
BPTH net income for the last year is -270,000 USD.
How many employees does Bio-Path have?▼
As of July 28, 2026, the company has 1 employees.
In which sector is Bio-Path located?▼
Bio-Path operates in the Health & Wellness sector.
When did Bio-Path complete a stock split?▼
The last stock split for Bio-Path was on February 23, 2024 with a ratio of 1:20.
Where is Bio-Path headquartered?▼
Bio-Path is headquartered in Bellaire, United States.